 |
|
Advancing orphan drug development for rare diseases
Jung Min Ko
Clin Exp Pediatr. 2024;67(7):356-357. Published online 2023 Nov 17 DOI: https://doi.org/10.3345/cep.2023.01109
|
|
Citations to this article as recorded by
 Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis
Mohammed Alfaqeeh, Auliya A. Suwantika, Maarten J. Postma, Rizkia Andicha Putra, Jasmine Rani Aisyah, Fima Perdani Rahayu, Lubna Farhana, Muhammad Ilyas, Shofuro Sholihah, Neily Zakiyah
Value in Health.2026; 29(4): 678. CrossRef Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity
Olabisi Promise Lawal, Enibokun Theresa Orobator, Sokoya Itunuoluwa Dorcas, Victor Chiedozie Ezeamii, Evelyn Foster-Pagaebi, Muhammad Attahiru
Journal of Life Science and Public Health.2025; 1(1): 1. CrossRef Visual Research of Global Orphan Drug from a Bibliometric Perspective
Xiaoya Wen, Guangzhi Jin, Chunxing Wu
Drug Design, Development and Therapy.2025; Volume 19: 4201. CrossRef
|